Patents Examined by Jeffrey H Murray
  • Aminopyrimidines as ALK inhibitors
    Patent number: 11110090
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: September 7, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Jianyong Chen
  • Amino pyrimidine compound for inhibiting protein tyrosine kinase activity
    Patent number: 11111233
    Abstract: An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: September 7, 2021
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Xingye Ren, Jian Jin, Huanyin Li, Yixin Ai
  • Method for preparing oxaspirocycle derivative, and intermediate thereof
    Patent number: 11111236
    Abstract: A method for preparing an oxaspirocycle derivative and an intermediate thereof are described. The method reduces reaction steps, improves reaction yield, is simple and easy to operate, and is favorable for industrial large-scale production.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 7, 2021
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Wenhai Li, Weixing Qi, Zhenjun Qiu
  • MK2 inhibitors and uses thereof
    Patent number: 11098061
    Abstract: The present invention provides compounds of formula V: or pharmaceutically acceptable salts thereof, useful as inhibitors of MK2 kinases, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: August 24, 2021
    Assignee: Celgene CAR LLC
    Inventors: Matthew David Alexander, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Tao Wang, Zhendong Zhu
  • Indazole derivatives useful as glucagon receptor antagonists
    Patent number: 11098016
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: August 24, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Synthetic method for benzimidazo[1,2-c]quinazolin-6-ones
    Patent number: 11098049
    Abstract: The disclosure discloses a synthetic method for benzimidazo[1,2-c]quinazolin-6-ones and belongs to the field of organic synthesis. In the disclosure, an ?-ketoamide compound shown as Formula I and an o-phenylenediamine compound shown as Formula II are used as substrates and undergo a reaction under the action of a catalyst and a base to obtain benzimidazo[1,2-c]quinazolin-6-ones shown as Formula III. In the disclosure, benzimidazo[1,2-c]quinazolin-6-ones are prepared based on a novel and efficient action mechanism, and the disclosure has the advantages that the raw materials are cheap, the catalyst is cheap and easy to obtain, the reaction is efficient and environmentally friendly, the substrate range is wide, the yield is high, and the operation is simple.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: August 24, 2021
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Lianghua Zou, Fei Ren, Biao Liu, Kai Shi, Cheng Yan, Shuai Zhu, Hao Zhu, Yuhao Cheng, Zhekang Jia
  • Modulators of THR-? and methods of use thereof
    Patent number: 11091467
    Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: August 17, 2021
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, David McGowan, Jerome Deval
  • Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
    Patent number: 11084818
    Abstract: Disclosed are a nitrogen-containing heterocyclic compound, a preparation method thereof, an intermediate thereof, a pharmaceutical composition thereof and a use thereof. The nitrogen-containing heterocyclic compound is a compound of formula I or formula II, a tautomer thereof, an optical isomer thereof, a deuterated compound thereof, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof, which can be used for treating a disease associated with TLR7 activity. The nitrogen-containing heterocyclic compound has a relatively high TLR7 agonist activity, high selectivity and good safety.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 10, 2021
    Assignee: HEPO PHARMACEUTICAL CO., LTD.
    Inventors: Xuemei Liu, Pengfei Qian
  • Heterocycle derivatives as pesticides
    Patent number: 11083199
    Abstract: The invention relates to novel compounds of the formula (I), in which X, R1, R2, R3, and n have the meanings given above, to the use thereof as acaricides and/or insecticides for controlling animal pests and to methods and intermediates for the preparation thereof.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: August 10, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer CropScience Aktiengesellschaft
    Inventors: David Wilcke, Dominik Hager, Laura Hoffmeister, Nina Kausch-Busies, Marc Mosrin, Matthieu Willot, Ruediger Fischer, Kerstin Ilg, Ulrich Goergens, Andreas Turberg
  • Piperazine derivatives, pharmaceutical compositions and methods of use thereof
    Patent number: 11084807
    Abstract: The present invention relates to novel piperazine derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially for targeted therapy treatment of hyperproliferative disorders, including benign hyperproliferative disorders, cancer and pre-cancer conditions.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: August 10, 2021
    Assignee: VIDAC PHARAMA LTD.
    Inventors: Paul Salama, Vered Behar, Oren Menahem Becker
  • Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
    Patent number: 11077118
    Abstract: This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and/or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: August 3, 2021
    Assignee: DEMERX, INC.
    Inventor: Emeline Maillet
  • Crystalline tranilast salts and their pharmaceutical use
    Patent number: 11078155
    Abstract: The invention relates to crystalline tranilast salts. The crystalline tranilast salts, their preparation and their characterization are described and shown in the figures. The invention relates to pharmaceutical compositions containing a crystalline tranilast salt of the invention and a pharmaceutically acceptable carrier. The invention also relates to methods of treatment and the use of a therapeutically effective amount of a crystalline tranilast salt of the invention for treatment. The invention also relates to a method of preparing a liquid pharmaceutical composition comprising the step of dissolving a crystalline tranilast salt of the invention in a pharmaceutically acceptable solvent and to liquid pharmaceutical compositions prepared according to that method.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: August 3, 2021
    Assignee: NUFORMIX TECHNOLOGIES LIMITED
    Inventors: Joanne Holland, Christopher Frampton
  • Gamma-diketones for treatment and prevention of aging skin and wrinkles
    Patent number: 11077046
    Abstract: The present disclosure relates to compounds, cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: August 3, 2021
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: John Hood, Sunil Kumar KC, Osman Kibar, Charlene F. Barroga
  • Allosteric modulators of the mu opioid receptor
    Patent number: 11071731
    Abstract: Disclosed herein are compounds, of the class of amine-bearing heterocycles, which act as positive allosteric modulators and silent allosteric modulators of the mu opioid receptor. These compounds are useful for the treatment of pain, drug addiction, and other CNS derived maladies that are controlled directly or indirectly by activation of the mu opioid receptor. Methods for making and using the allosteric modulators disclosed herein are also provided.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: July 27, 2021
    Assignee: Chiromics, LLC
    Inventors: Joel Francis Austin, Michael David VanHeyst, James S. Harvey, Elizabeth Gerig Rowley, Christophe Lamarque-Lacoste
  • Fused triazolo-pyrimidine compounds having useful pharmaceutical application
    Patent number: 11066410
    Abstract: A compound and/or a pharmaceutically acceptable salt thereof has the following formula A: These compounds can be PIKfyve kinase inhibitors.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: July 20, 2021
    Assignee: 3100 Central Expressway LLC
    Inventors: Sergei Romanov, Robert Greenhouse, Nikolai Sepetov
  • [1,2,4]triazolo[1,5-c]pyrimidine derivative as Areceptor inhibitor
    Patent number: 11066411
    Abstract: Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to A2A receptor. The R1, R2, R3, ring A, ring B, n, and m are as defined in the specification.
    Type: Grant
    Filed: April 8, 2018
    Date of Patent: July 20, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Yanxin Yu, Xinde Chen, Li Zhang, Zhaoguo Chen, Cheng Xie, Xiaofei Wang, Linghui Wu, Guoping Hu, Jian Li, Shuhui Chen
  • Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors
    Patent number: 11065257
    Abstract: The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: July 20, 2021
    Assignee: LEO Pharma A/S
    Inventors: Xifu Liang, Jens Larsen, Simon Feldbaek Nielsen, Peter Andersen
  • Heterocycle derivatives as pesticides
    Patent number: 11058115
    Abstract: The invention relates to novel compounds of the formula (I) in which X, R1, R2, R3 and n have the definitions given above, to the use thereof as acaricides and/or insecticides for control of animal pests and to processes and intermediates for preparation thereof.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: July 13, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer CropScience Aktiengesellschaft
    Inventors: David Wilcke, Ruediger Fischer, Dominik Hager, Laura Hoffmeister, Nina Kausch-Busies, Marc Mosrin, Matthieu Willot, Kerstin Ilg, Ulrich Goergens, Andreas Turberg
  • Methods to induce targeted protein degradation through bifunctional molecules
    Patent number: 11059801
    Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of cancer.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: July 13, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: James Bradner, Dennis Buckley, Georg Winter
  • Dihydropyranopyrimidines for the treatment of viral infections
    Patent number: 11053256
    Abstract: This invention relates to dihydropyranopynmidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 6, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Jérôme Émile Georges Guillemont, David Craig McGowan, Werner Constant Johan Embrechts, Ludwig Paul Cooymans, Laurent Calmus